New hope for lymphoma patients: glofitamab combo faces standard care in trial
NCT ID NCT07599423
First seen Jun 26, 2026 · Last updated Jul 14, 2026 · Updated 3 times
Summary
This study tests whether adding the immunotherapy drug glofitamab to standard chemotherapy (gemcitabine and oxaliplatin) works better than usual treatments for people with large B-cell lymphoma that has returned or not responded to first therapy. About 96 adults will be randomly assigned to get either the new combo or standard care, which may include a stem cell transplant. The main goal is to see how long patients stay free of cancer progression or death.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- glofitamab (a drug that helps the immune system attack cancer cells) combined with gemcitabine and oxaliplatin (chemotherapy)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with hard-to-treat large B-cell lymphoma that has come back or not responded to initial therapy.
- What could go wrong
- This is a Phase 2 trial with only 96 participants, so results are preliminary. The drug combination may cause serious side effects like cytokine release syndrome, and it may not work better than current standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a Two-Drug combo keep aggressive lymphoma at bay?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can a single shot build a cancer army inside the body?
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas